Company
Tempus AI
Chicago-based precision-medicine company (Nasdaq: TEM), founded in 2015 by Eric Lefkofsky; built its business on genomic and clinical data before expanding into a family of FDA-cleared ECG-AI screening tools, of which this is the fourth.
2 stories
Regulatory News has published 2 stories about Tempus AI between 25 August 2026 and 30 September 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 30 September 2026.
This page is generated from Regulatory News’ editorial coverage of Tempus AI. It is not an advertisement.
